title: Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
authors.forename: Fábio R
authors.initials: FR
authors.lastname: Kerbauy
authors.forename: Morgani
authors.initials: M
authors.lastname: Rodrigues
authors.forename: Fábio Pires
authors.initials: FP
authors.lastname: de Souza Santos
authors.forename: Jairo Nascimento
authors.initials: JN
authors.lastname: Sobrinho
authors.forename: José Mauro
authors.initials: JM
authors.lastname: Kutner
authors.forename: Margareth A
authors.initials: MA
authors.lastname: Torres
authors.forename: Andreza Alice Feitosa
authors.initials: AA
authors.lastname: Ribeiro
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
authors.forename: Nelson
authors.initials: N
authors.lastname: Hamerschlak
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002066:Busulfan / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine